BRAFTOVI + MEKTOVI continued to show substantial antitumor activity after a minimum follow up of approximately three years, corresponding to the longest duration of response and progression-free ...
BOULDER, Colo., May 21, 2019 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) today announced positive results from the interim analysis of the Phase 3 BEACON CRC trial evaluating the combination ...
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the Supplemental New Drug Applications (sNDAs) for BRAFTOVI ® ...
BRAFTOVI + MEKTOVI continued to show a substantial median overall survival benefit of 47.6 months in treatment-naïve patients with BRAF V600E-mutant metastatic non-small cell lung cancer after ...
BOULDER, Colo., July 27, 2018 /PRNewswire/ -- Array BioPharma Inc. (NASDAQ: ARRY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) ...
BOULDER, Colo., May 29, 2019 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) announced that that it will present data from the Phase 3 COLUMBUS Trial of BRAFTOVI + MEKTOVI in advanced BRAF-mutant ...
The triplet combination of BRAFTOVI, MEKTOVI and ERBITUX for the treatment of patients with BRAFV600E -mutant mCRC is investigational and not approved by the EC. About Colorectal Cancer Worldwide, ...
Pfizer Inc. - Business Wire - Sun Oct 19, 1:30AM CDT At the time of this analysis, the safety profile of BRAFTOVI + MEKTOVI was consistent with previous findings. The most common (≥30%) ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback